Market Cap 10.48B
Revenue (ttm) 4.44B
Net Income (ttm) 338.00M
EPS (ttm) N/A
PE Ratio 22.91
Forward PE 23.72
Profit Margin 7.61%
Debt to Equity Ratio 0.60
Volume 5,269,900
Avg Vol 5,578,218
Day's Range N/A - N/A
Shares Out 496.86M
Stochastic %K 12%
Beta 1.71
Analysts Strong Sell
Price Target $24.22

Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. It offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Crede...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 877 352 6261
Address:
2500 Innovation Way, Greenfield, United States
GettnFibbywIT
GettnFibbywIT Nov. 14 at 7:54 PM
$ELAN $XPH Elanco Animal Health (XPH)- Wait a minute, a pull back at the technical 50% Fib level of the July '21 to May '23 draw down level, with a price + momentum divergence developing - Who knew? Coincidence perhaps......I think not:
0 · Reply
Patstock
Patstock Nov. 12 at 12:37 PM
$ELAN it is eating $ZTS lunch. First simparica trio got hit and now they are aiming for Cytopoint inj
0 · Reply
Trader_Ty
Trader_Ty Nov. 10 at 2:07 AM
$ELAN IPO double bottom. Maybe a run to ATHs
0 · Reply
JarvisFlow
JarvisFlow Nov. 6 at 5:35 PM
UBS has updated their rating for Elanco Animal Health ( $ELAN ) to Buy with a price target of 27.
0 · Reply
DonCorleone77
DonCorleone77 Nov. 5 at 11:51 AM
$ELAN Elanco reports Q3 EPS 19c, consensus 13c -- Q3 revenue $1.14B, consensus $1.09B -- Raises FY25 adjusted EPS view to 91c-94c, consensus 91c -- Raises FY25 revenue view to $4.65B-$4.67B from $4.57B-$4.62B, consensus $4.6B. -- Raises FY25 adjusted EBITDA view to $880M-$900M from $850M-$890M. -- Sees Q4 adjusted EPS 9c-12c, consensus 14c -- Sees Q4 revenue $1.09B-$1.11B, consensus $1.08B. -- Sees Q4 adjusted EBITDA $168M-$188M.
0 · Reply
lecorb
lecorb Nov. 5 at 11:43 AM
$ELAN Elanco press release (ELAN): Q3 Non-GAAP EPS of $0.19 beats by $0.06. Revenue of $1.X.14B (+10.7% Y/Y) beats by $50M. Full Year 2025 Guidance: Raising revenue guidance to $4.X,645 million to $4.X,670 million; expect accelerating organic constant currency revenue growth of 6% to 6.5% vs. 3% in 2024 Raising 2025 innovation revenue target by $100 million at the midpoint of the range to $840 to $880 million Reported Net Loss of $56 million to $41 million, raising guidance for Adjusted EBITDA to $880 million to $900 million Reported Loss Per Share of $0.11 to $0.08, raising guidance for Adjusted EPS to $0.91 to $0.94 2025 year-end net leverage ratio target improved to 3.7x to 3.8x, enabled by year-to-date execution and disciplined working capital management
0 · Reply
BeanSupreme
BeanSupreme Nov. 4 at 4:58 PM
$ZTS Big fears here that they are losing market share to $ELAN
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Oct. 31 at 11:43 AM
$ELAN RSI: 91.94, MACD: 0.8441 Vol: 0.92, MA20: 21.15, MA50: 19.68 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
OptionRunners
OptionRunners Oct. 29 at 5:43 PM
$ELAN Buyer of the January 16th 2026 $20 puts 4,750 times for $1.X.07 against OI of 4,918 contracts. Appears to be adding, check the change in OI for confirmation. Earnings on 11/5
0 · Reply
OptionRunners
OptionRunners Oct. 28 at 2:57 PM
$ELAN Buyer of the January 16th 2026 $20 puts 3,500 times for $1.04 ahead of earnings on 11/5
0 · Reply
Latest News on ELAN
Elanco Animal Health Reports Third Quarter 2025 Results

Nov 5, 2025, 6:27 AM EST - 11 days ago

Elanco Animal Health Reports Third Quarter 2025 Results


Elanco to Host Investor Day on December 9

Oct 16, 2025, 4:32 PM EDT - 4 weeks ago

Elanco to Host Investor Day on December 9


Elanco Animal Health Reports Second Quarter 2025 Results

Aug 7, 2025, 6:27 AM EDT - 3 months ago

Elanco Animal Health Reports Second Quarter 2025 Results


Elanco's dog flu vaccine gets USDA nod

Jul 9, 2025, 10:01 AM EDT - 4 months ago

Elanco's dog flu vaccine gets USDA nod


Elanco Releases 2024 Impact Report and Introduces New Framework

Jun 26, 2025, 1:00 PM EDT - 5 months ago

Elanco Releases 2024 Impact Report and Introduces New Framework


Elanco to Participate in the Upcoming Investor Conferences

May 16, 2025, 8:00 AM EDT - 6 months ago

Elanco to Participate in the Upcoming Investor Conferences


Elanco: Deleveraging Takes Time

May 12, 2025, 4:26 AM EDT - 6 months ago

Elanco: Deleveraging Takes Time


Elanco Animal Health Reports First Quarter 2025 Results

May 7, 2025, 6:27 AM EDT - 6 months ago

Elanco Animal Health Reports First Quarter 2025 Results


Trade Tracker: Sarat Sethi buys Zoetis and sells Elanco

Apr 23, 2025, 1:16 PM EDT - 7 months ago

Trade Tracker: Sarat Sethi buys Zoetis and sells Elanco

ZTS


GettnFibbywIT
GettnFibbywIT Nov. 14 at 7:54 PM
$ELAN $XPH Elanco Animal Health (XPH)- Wait a minute, a pull back at the technical 50% Fib level of the July '21 to May '23 draw down level, with a price + momentum divergence developing - Who knew? Coincidence perhaps......I think not:
0 · Reply
Patstock
Patstock Nov. 12 at 12:37 PM
$ELAN it is eating $ZTS lunch. First simparica trio got hit and now they are aiming for Cytopoint inj
0 · Reply
Trader_Ty
Trader_Ty Nov. 10 at 2:07 AM
$ELAN IPO double bottom. Maybe a run to ATHs
0 · Reply
JarvisFlow
JarvisFlow Nov. 6 at 5:35 PM
UBS has updated their rating for Elanco Animal Health ( $ELAN ) to Buy with a price target of 27.
0 · Reply
DonCorleone77
DonCorleone77 Nov. 5 at 11:51 AM
$ELAN Elanco reports Q3 EPS 19c, consensus 13c -- Q3 revenue $1.14B, consensus $1.09B -- Raises FY25 adjusted EPS view to 91c-94c, consensus 91c -- Raises FY25 revenue view to $4.65B-$4.67B from $4.57B-$4.62B, consensus $4.6B. -- Raises FY25 adjusted EBITDA view to $880M-$900M from $850M-$890M. -- Sees Q4 adjusted EPS 9c-12c, consensus 14c -- Sees Q4 revenue $1.09B-$1.11B, consensus $1.08B. -- Sees Q4 adjusted EBITDA $168M-$188M.
0 · Reply
lecorb
lecorb Nov. 5 at 11:43 AM
$ELAN Elanco press release (ELAN): Q3 Non-GAAP EPS of $0.19 beats by $0.06. Revenue of $1.X.14B (+10.7% Y/Y) beats by $50M. Full Year 2025 Guidance: Raising revenue guidance to $4.X,645 million to $4.X,670 million; expect accelerating organic constant currency revenue growth of 6% to 6.5% vs. 3% in 2024 Raising 2025 innovation revenue target by $100 million at the midpoint of the range to $840 to $880 million Reported Net Loss of $56 million to $41 million, raising guidance for Adjusted EBITDA to $880 million to $900 million Reported Loss Per Share of $0.11 to $0.08, raising guidance for Adjusted EPS to $0.91 to $0.94 2025 year-end net leverage ratio target improved to 3.7x to 3.8x, enabled by year-to-date execution and disciplined working capital management
0 · Reply
BeanSupreme
BeanSupreme Nov. 4 at 4:58 PM
$ZTS Big fears here that they are losing market share to $ELAN
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Oct. 31 at 11:43 AM
$ELAN RSI: 91.94, MACD: 0.8441 Vol: 0.92, MA20: 21.15, MA50: 19.68 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
OptionRunners
OptionRunners Oct. 29 at 5:43 PM
$ELAN Buyer of the January 16th 2026 $20 puts 4,750 times for $1.X.07 against OI of 4,918 contracts. Appears to be adding, check the change in OI for confirmation. Earnings on 11/5
0 · Reply
OptionRunners
OptionRunners Oct. 28 at 2:57 PM
$ELAN Buyer of the January 16th 2026 $20 puts 3,500 times for $1.04 ahead of earnings on 11/5
0 · Reply
LtFrankDrebin
LtFrankDrebin Oct. 26 at 8:30 PM
$ELAN Elanco received an emergency-use authorization for it's screwworm treatment, the first time this authorization has happened for an animal drug. This is because this is much bigger than treating a pet worm, since the FDA said this parasite poses a threat to livestock and food security near the US-Mexico border, as reported by the WSJ. https://www.wsj.com/health/healthcare/elanco-animal-health-obtains-fda-authorization-for-screwworm-treatment-c5566ad7
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Oct. 24 at 9:42 PM
0 · Reply
SuperGreenToday
SuperGreenToday Oct. 22 at 11:34 AM
$ELAN Share Price: $21.62 Contract Selected: Apr 17, 2026 $20 Calls Buy Zone: $2.52 – $3.12 Target Zone: $4.46 – $5.45 Potential Upside: 67% ROI Time to Expiration: 176 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
JarvisFlow
JarvisFlow Oct. 20 at 10:20 PM
UBS has adjusted their stance on Elanco Animal Health ( $ELAN ), setting the rating to Buy with a target price of 19 → 25.
0 · Reply
LtFrankDrebin
LtFrankDrebin Oct. 20 at 12:12 PM
$ELAN There aren't many stocks out there with this good of a 6 month chart. A gradual rise up with upgrade after upgrade along the way.
0 · Reply
StealthTickerg
StealthTickerg Oct. 17 at 4:01 PM
$ELAN Gross margin near 64 percent on 894k revenue in 2024 says the unit model has teeth, push volumes through EU partnerships and fixed costs dilute fast, at 5M to 15M sales even a 6x to 10x P S resets EV hard
0 · Reply
ivanhoff
ivanhoff Oct. 17 at 3:01 PM
Only four stocks on the new 52-week relative strength high list so far this morning - $ELAN $MLYS $ASX $CLS
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 17 at 2:45 PM
Enter: $ELAN NOV 21 2025 $21 CALLS Buy in Price: $1.10 - $1.45 Take Profit: $2.12 Stop Bleeding: $0.97 ROI Potential: 93% Exit Within: 2 Weeks https://moneygroup.us/alerts
0 · Reply
LtFrankDrebin
LtFrankDrebin Oct. 15 at 12:10 PM
$ELAN Zenrelia is their new pet allergy drug, and it's becoming increasingly popular in vet offices across the country. It's considerably cheaper than the popular pet allergy drug Apoquel, and many are finding it more effective. With dog and cat allergies becoming more and more of an issue, many vets across the country are prescribing this drug instead of Apoquel to treat them.
0 · Reply
JustB3liev3
JustB3liev3 Oct. 13 at 1:48 PM
$NVNI not advice, the big algos are at risk of lending shares and hedging downside bets. Until the Vix and Spy cool off, im going to wait it out. Everything is at the verge of another pop or a massive drop. I sold $CHEWY $OCUGEN $ELAN $NVNI $COSM $ANGX will wait it out and see what I can do. All for gains. But will decide what to do with capital later. Liquidated 30k down to about 5k.
1 · Reply
JustB3liev3
JustB3liev3 Oct. 10 at 3:58 PM
$NVNI $COSM $ELAN $ANGX sold most of my positions to offset taxes this year. Im not paying gain on unrealized profits that I took to soon. Regained my capital for other things for now. Ill redistribute my small wealth when the time is right. What a beautiful year, I broke even on the year sadly due to bad options trading and by choice due to taking my profits and putting back in nvni for a loss. but either way! went on a 30k run over 3 months after being down 10k! What a win in my books. Average of 300% on all my positions!! Wooh!!
0 · Reply
JustB3liev3
JustB3liev3 Oct. 7 at 11:09 AM
$NVNI still here $COSM still being lame. $OCGN loving it. $ELAN price target increase. Im now up 900% on my options. Guess im a shitty trader too cause I cant always prevent being blindsided ^-^ Just looked, I have almost 100% on all stocks on my portfolio in less than a year. Some a few months. And some well over 100% just averaged up.. or bought back in^-^ haha tax offset of profits , for huge gains and government gets there part. Either way I win.
0 · Reply